Raymond James lowered the firm’s price target on Danaher (DHR) to $275 from $300 and keeps an Outperform rating on the shares. The firm is taking a modestly conservative tack on the recovery ramp for Life Sciences Tools & Services through 2025 as well as layering in a substantially more significant foreign exchange headwind given movement in the dollar since Q3 results, the analyst tells investors in a research note. Danaher continues to benefit from its blue chip status, making it likely to see early inflows when sentiment is improving.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Danaher price target lowered to $250 from $255 at Goldman Sachs
- Danaher sees Q4 revenue up low-single digit percent range year-over-year
- Danaher announces investment partnership in Innovaccer
- Danaher price target lowered to $285 from $305 at Citi
- Danaher price target lowered to $268 from $278 at Evercore ISI